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Abstract Soluble CD21 (sCD21) is the ectodomain of
the CD21 glycoprotein released by shedding from the
cellular membrane. The ectodomain of CD21 is capable
of binding complement fragments, Epstein-Barr virus
(EBV) and CD23. Functionally sCD21 can activate
monocytes and abrogate B-cell/follicular dendritic cell
interaction, thereby inhibiting antibody production by
antigen primed B cells. Levels of sCD21 vary in several
clinical conditions. Here we analyzed sCD21 in synovial
ﬂuids and sera in arthritic patients. sCD21 concentra-
tions were consistently lower in synovial ﬂuids compared
to paired sera samples from the same patients. In con-
trast to healthy donors, sCD21 levels are signiﬁcantly
reduced in rheumatoid arthritis patient’s sera. Potential
causes and consequences of the data are discussed.
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Introduction
Rheumatoid arthritis (RA) is a systemic chronic
inﬂammatory disease. The innate immune system may
play an important role in the complex pathophysiology
[1, 2] because complement activation products are ele-
vated in RA [3, 4].
Proteolytic cleavage of membrane bound proteins,
known as shedding, releases the ectodomain part of the
molecule from the cell surface. Usually these ectodo-
mains retain the capability to bind to all known ligands
[5, 6].
CD21 is the receptor for C3d complement fragments
bound to microbial surfaces or immune complexes, and
the Epstein-Barr virus (EBV). CD21 ampliﬁes the signal
through the B cell receptor and is required for B cell
activation to low aﬃnity antigen and survival of B cells
during the germinal center reaction [7]. CD21 is shed
above the cellular membrane and is found in the circu-
lation. It has been found at higher concentrations in
patients with certain B lymphomas, EBV infections [8, 9]
and was shown to activate monocytes through its ligand
CD23 [10]. Furthermore, soluble CD21 (sCD21) could
be a modulator of immunity because it can block fol-
licular dendritic cell (FDC) dependent B cell activation
[11, 12].
Surface expression of CD21 is reduced in synovial
lymphocytes as compared to peripheral blood lym-
phocytes and in activated T cells [13, 14]. We have
recently shown that the concentration of sCD21 is low
in systemic lupus erythomatodes (SLE) [15], Sjo¨gren’s
syndrome [15] and RA serum [16] compared to heal-
thy persons’ sera but not in juvenile arthritis [15].
Analysis of paired synovial ﬂuids and sera from
juvenile arthritis patients showed low sCD21 concen-
tration in synovial ﬂuids compared to sera [15].
Therefore we were interested to analyze sCD21 con-
centrations in other forms of arthritis synovial ﬂuids
as well. Using an ELISA we measured sCD21 in
synovial ﬂuids and sera of the same patients, and
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furthermore we extended our previous analysis of RA
patients and healthy individuals.
Patients and methods
Human samples, cells, antibodies and reagents
Nine consecutive patients with diﬀerent forms of arthri-
tis, the majority of them with RA, requiring removal of
joint ﬂuid were recruited from the out-patient clinic of
the Division of Rheumatology at the Kantonsspital St.
Gallen after obtaining informed consent. All patients
suﬀered from a well-deﬁned arthritic disorder diagnosed,
as in the case of RA, using the ACR-classiﬁcation criteria
[17]. Undiﬀerentiated arthritis was deﬁned as non-
remittent oligoarthritis in the absence of rheumafactor,
anti-CCP antibodies and without evidence for spond-
arthropathy, psoriasis or reactive arthritis. Human sera
from RA patients (n=83) were collected from out-clinic
patients at the Freiburg University Medical Center and
from healthy donors (n=63). In all instances patients
gave informed consent. Mononuclear cells were counted
and neutrophil granulocytes diﬀerentiated from lym-
phocytes and monocytes using standard methods.
Monoclonal anti-CD21 antibodies BU32 (IgG1) and
THB5 (IgG2a) were puriﬁed by aﬃnity chromatography
with protein-G sepharose (Amersham, Freiburg, Ger-
many). BU32 was biotinylated using Biotintag micro kit
(Sigma-Aldrich, Switzerland). For standardization,
aliquots of a human sera were used. Values are given in
arbitrary units. A sandwich ELISA was performed to
quantitate sCD21 levels in human serum/plasma. The
monoclonal antibodies THB5 and biotinylated BU32
were used as capture antibody and revealing antibody
respectively. Brieﬂy, THB5 was coated onto an ELISA
plate (TPP, Trassadingen, Switzerland) at a concentra-
tion of 2 lg/ml in PBS for 12–15 h at 4C. Plates were
blocked with 3% bovine serum albumin in PBS for 2 h
at room temperature. The serum/plasma samples at
appropriate dilutions were added in triplicates to the
plates along with the standard. The plates were incu-
bated at 4C for 12–15 h, washed twice and then incu-
bated for 2 h with BU32-biotin. After four washes,
streptavidin coupled to horseradish peroxidase was
added for 1 h and then H2O2/o-phenylenediamine as
substrate/coloring agent for 30 min. The enzyme reac-
tion was quantiﬁed by taking OD at 450 nm in an
ELISA reader (Tecan, Switzerland) and sCD21 con-
centrations were calculated extrapolating from the
standard graph.
Statistics
Statistical calculations and graphical illustrations were
performed using Instat/Prism software. Mann–Whitney
tests to obtain nonparametric two-tail P value were
performed.
Results
Soluble CD21 in synovial ﬂuid and serum
We analyzed sCD21 concentrations in synovial ﬂuids
and sera of the same patients. sCD21 concentration in
synovial ﬂuids ranged from 0 to 73 units sCD21/ml
(mean 49.24) (Fig. 1). Serum levels of sCD21 in this
cohort ranged from 119 to 169 units sCD21/ml (mean
142.58), and were in all cases higher compared to the
synovial ﬂuid of the same patients (Fig. 1). Using the
non-parametric Mann–Whitney test, the diﬀerence be-
tween the synovial ﬂuid and serum sCD21 concentra-
tions was calculated as being highly signiﬁcant
(P=0.0001). Thus, the concentration of sCD21 diﬀers
signiﬁcantly between synovial ﬂuid and blood.
Soluble CD21 concentrations in sera of patients
with rheumatoid arthritis
We have previously shown comparatively low levels of
sCD21 in the sera of RA patients [16]. In the present
study this analysis was extended using 63 sera samples
from a diﬀerent set of RA patients and compared these
results to 80 sera from a diﬀerent set of healthy donors.
Values of RA sera ranged from 59 to 518 unit sCD21/ml
(mean 159.60) and in HD sera from 93 to 570 unit
sCD21/ml (mean 196.70). The sCD21 concentrations
were found to be lower in RA than in normal controls
revealing a statistically highly-signiﬁcant reduction
(P=0.0004)(Fig. 2).
Methotrexate (MTX) stimulates adenosine release
from connective tissue cells [18]. This could stimulate
purinergic P2 receptors, which are known to induce
shedding of CD62L and CD23 [19]. The same mecha-
nism might induce CD21 shedding as well. Therefore we
Fig. 1 Soluble CD21 concentration in synovial ﬂuid and sera. Sera
and synovial ﬂuid were tested for sCD21 concentration by ELISA.
11 sera (ﬁlled triangle) and 11 synovial ﬂuids (ﬁlled square) from
patients detailed in Table 1 were analyzed for sCD21 content. Sera
and synovial ﬂuid were collected at the same time. Diﬀerences
between synovial ﬂuid and sera were highly signiﬁcant (P=0.0008)
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compared sCD21 levels in patients treated with MTX
(n=37) or not treated with MTX (n=16). There was no
signiﬁcant diﬀerence between the two groups. Thus low
dose MTX did not inﬂuence CD21 shedding signiﬁ-
cantly.
Discussion
This study demonstrates that synovial ﬂuids contain less
sCD21 than sera from the same patients, and that the
levels of sCD21 in the sera of RA patients were signiﬁ-
cantly lower than those of healthy donors. Even though
clearly not powered to answer this question, clinical data
of the paired synovial ﬂuid/sera cohort did not suggest a
possible inﬂuence of disease duration, or the absence or
kind of therapy used on the levels of sCD21 in either
sera or synovial ﬂuid, nor did the amounts of inﬂam-
matory cells in the synovial ﬂuid.
We have previously shown that the reduction of
sCD21 in adult autoimmune diseases is not due to the
age of the patients, nor related to the presence of rheu-
matoid factor [15, 16]. Interestingly, this was not the
case in juvenile arthritis where we found normal
amounts in sera [15]. Whether this reﬂects a qualitative
or quantitative diﬀerence in CD21 shedding is not clear.
However, when we compared concentrations of sCD21
according to age we found more sCD21 in sera of do-
nors below age 20 [16]. Low sCD21 in the circulation
could be due to increased complement activation prod-
ucts leading to increased clearance of bound sCD21from
plasma. In RA patients an even slightly-elevated turn-
over of C3 (1 g/l in healthy human sera) might be suf-
ﬁcient to ‘‘neutralize’’ sCD21 (about 200–300 lg/l in
healthy persons sera). Elevated concentrations of pro-
tease inhibitors such as alpha-1-antitrypsin could pre-
vent shedding of CD21 from the lymphocyte surface by
inhibiting yet unidentiﬁed proteases associated with the
cell membrane [20].
The switched memory B cell pool is enlarged in RA
patients, and CD38+ plasma-cell-like B cells are present
in higher numbers [21]. The lower concentrations of
sCD21 are most likely not related to properties of the
peripheral blood B cell pool alone, since peripheral
blood B cells from RA patients produce amounts of
sCD21 comparable to those from healthy individuals
[16]. A possible explanation is that the majority of
sCD21 is produced by other cell types or by B cells in
diﬀerent locations, for example in the spleen. It is also
possible that during autoimmunity the immune system
Table 1 Patients with diﬀerent kinds of arthritis
Sample name DOB Kind of
arthritis
sCD21 Gender Duration
of disease
DMARD/pred Cell-number
in SF
TSG 01 - SF 1953 UA 33.81 F 1 year MTX/pred 1200/7
TSG 01 serum 1953 UA 168.69 F
TSG 03 - SF 1953 RA 0 F 30 year Leﬂu/pred 7800/57
TSG 03 serum 1953 RA 136.72 F
TSG 05 SF 1927 RA 67.22 F 16 year MTX/inﬂixi/pred 83000/80
TSG 05 serum 1927 RA 137.08 F
TSG 10 SF 1924 RA 60.18 M 7 year MTX/inﬂixi/pred 25400/55
TSG 10 serum 1924 RA 166.08 M
TSG 11 SF 1979 RA 61.61 F 2 year None 26300/68
TSG 11 serum 1979 RA 131.08 F
TSG 13 SF 1955 SpondA 59.16 M 4 weeks None 39650/53
TSG 13 serum 1955 SpondA 119.25 M
TSG 14 SF 1945 RA 44.65 M 3 year None 35400/nd
TSG 14 serum 1945 RA 138.64 M
TSG 15 SF 1926 RA 73.02 F 5 year Pred ND
TSG 15 serum 1926 RA 144.94 F
TSG 16 SF 1926 RA 43.49 F 5 year Pred ND
TSG 16 serum 1926 RA 140.7 F
sCD21 in ng/ml; numbers of mononuclear cells per ll/percentage of neutrophils are shown in column ‘‘cell-number in SF’’
SF synovial ﬂuid, DOB date of birth, UA undiﬀerentiated arthritis, RA rheumatoid arthritis, SpondA Spondarthropathy with peripheral
arthritis, OA osteoarthritis, DMARD disease-modifying antirheumatic drug, pred prednisone, leﬂu leﬂunomide, MTX ethotrexate, inﬂixi
inﬂiximab, ND not determined
Fig. 2 Serum sCD21 concentration in rheumatoid arthritis. sCD21
concentrations were measured by ELISA from conﬁrmed rheuma-
toid arthritis patients (n=63, ﬁlled square) and compared with
healthy controls (n=80, ﬁlled triangle). Diﬀerences between RA
sera and HD sera were highly signiﬁcant (P=0.0004)
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suppresses further responses. This might lead to lower
sCD21 concentrations because activation of B cells leads
to CD21 shedding [22]. Our data suggest that low-dose
MTX does not signiﬁcantly inﬂuence CD21 shedding.
Lower amounts of sCD21 have been found before in
synovial ﬂuids from patients with juvenile arthritis [15].
The protein content of the synovial ﬂuid is in part de-
rived from the pannus tissue and inﬂammatory cells in
the arthritic joint (for example secreted molecules such
as cytokines). Previously we reported reduced expression
of CD21 in synovial ﬂuid compared to blood-derived
mononuclear cells [13]. This could explain the low levels
of sCD21 in the synovial ﬂuids observed here.
In conclusion, we found lower levels of sCD21 in
synovial ﬂuid compared to sera from the same patients.
The reduction of sCD21 serum levels seen in autoim-
mune arthritis such as RA suggests a role of the innate
immune system in autoimmune reactions and possibly in
the pathogenesis of these conditions.
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